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Background: Telomerase deficiency has been associated with inadequate differentiation of mesenchymal stem
cells. However, the effect of telomerase deficiency on differential regulation of osteoblast specific genes, based on
functional gene grouping, during in vitro osteoblast differentiation has not been reported before.
Results: To examine these effects, Terc-/- BMSCs (bone marrow stromal stem cells) were employed which exhibited
reduced proliferation during in vitro osteogenesis along with increased population doubling time and level
compared to wild type (WT) BMSCs during the normal culture. Osteogenic super array at day 10 of osteoblast
differentiation revealed that telomerase deficiency strongly affected the osteoblast commitment by down-regulating
Runx2, Twist and Vdr – known transcription regulators of osteogenesis. Similarly, in Terc-/- BMSCs a marked reduction in
other genes engaged in various phases of osteoblast differentiation were observed, such as Fgfr2 involved in bone
mineralization, Phex and Dmp1 engaged in ossification, and Col11a1 and Col2a1 involved in cartilage condensation. A
similar trend was observed for genes involved in osteoblast proliferation (Tgfb1, Fgfr2 and Pdgfa) and bone mineral
metabolism (Col1a1, Col2a1, Col1a2 and Col11a1). More profound changes were observed in genes engaged in
extracellular matrix production: Col1a1, Col1a2, Mmp10, Serpinh1 and Col4a1.
Conclusion: Taken together, these data suggest that telomerase deficiency causes impairment of BMSCs differentiation
into osteoblasts affecting commitment, proliferation, matrix mineralization and maturation. Thus, modulating
telomerase in BMSCs with advanced aging could improve BMSCs responsiveness towards osteoblast differentiation
signals, optimal for osteoblast commitment, proliferation and maturation processes.
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Osteoporosis is a disease of increased bone/skeletal fra-
gility common in the elderly and estrogen deficient post-
menopausal women [1,2]. Bone homeostasis is strictly
maintained by a well coordinated venture and steadiness
between bone formation by osteoblasts and bone resorp-
tion by osteoclasts [3]. However, disruption in any of
these above mentioned processes leads to skeletal/bone
fragility i-e., osteoporosis [3]. In this regard, role of oste-
oclasts in bone resoption have extensively been studied* Correspondence: hamid.pharmacy@pu.edu.pk
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unless otherwise stated.and many treatments are targeted at preventing bone
resorption, while little attention is paid towards bone
anabolic effects by enhancing osteoblasts and osteocytes
functions [3,4]. Therefore, equally important is to study
the physical factors and instigators that can contribute
towards a decline in osteoblast functions with advanced
aging. Osteoblasts are derived from bone marrow stro-
mal cells (BMSCs) also known as mesenchymal stem
cells (MSCs) capable of differentiating into multiple line-
ages i-e., osteoblasts, chondrocytes and adipocytes [5],
thus acting as the primary source of skeletal repair [6].
Tissue homeostasis is exceptionally maintained by a
strict balance between cell loss and cell replacement dur-
ing the course of tissue/organ life [7,8]. However, with
aging and in degenerative diseases, this balance declines
progressively resulting in reduced supply of new cells toentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tissue integrity and function along with reduced regener-
ation capacity upon damage [9]. Therefore, with aging,
owing to several factors including telomerase deficiency,
functional and numerical decline of BMSCs resulted in
the compromised ability of BMSCs to repair the skeleton
and maintain skeletal homeostasis [10-12].
Telomerase was first discovered by Greider et al. [13]
in the extracts of the protozoan Tetrahymena thermophila.
Telomerase plays an essential role in the maintenance of
choromosomal ends that is telomeres - G-rich simple re-
peat sequences (TTAGGG) that are synthesized by a spe-
cial reverse transcriptase called Telomerase [14,15]. This
enzyme requires a template to act which is the RNA com-
ponent of telomerase i.e, TERC [15,16]. Telomerase is
inactive in most somatic cells but active in germ cells, stem
cells and actively dividing cells [17]. Telomerase deficient
mice (Terc-/-) have been instrumental in delineating the
impact of telomere shortening in context of whole organ-
ism [18]. Disease states that appear in Terc-/- reiterate the
disease states, with more or less same etiology, in humans
characterized by short telomere in the cells as a result of
excessive proliferation [19-21].
For clinical purposes, BSMCs are expanded in vitro to
attain the desired number of cells which are not avail-
able from young marrow donors or through any other
source, whereas the frequency and quality of BMSCs de-
cline further with aging [22,23]. Yet, little attention is
paid towards in vitro differentiation hitches encountered
by BMSCs during the course of aging with telomerase
deficiency. In this study, we performed osteogenic tran-
scriptional profiling of telomerase deficient BMSCs during
in vitro osteoblast differentiation and found significant
disruption in normal osteogenic gene expression profiles.
Data suggest that telomerase deficiency in BMSCs can
cause noteworthy effect on the expression of genes vital
for skeletal development, bone mineral metabolism, cell
growth and differentiation, extra-cellular matrix produc-
tion and transcription regulation to initiate and maintain
normal osteogenesis.
Methods
Mice breeding, genotyping & handling
Terc deficient mice (Terc-/- Strain-004132) were purchased
from Jackson laboratory and kept in a pathogen-free
environment on standard chow. Terc-/- were inter-crossed
to generate 3rd generation Terc-/- (Terc-/-- G3) mice, and
were maintained in a C57BL/6J background. Wild type
Terc+/+ mice were employed as controls. Genotyping
was performed according to the protocol recommended
by Jackson laboratory. NOD/MrkBomTac-Prkdcscid mice
(NOD/SCID mice) were purchased from Taconic, Denmark.
The Danish Animal ethical committee approved all the
mouse experiments.Bone marrow stromal cell isolation
Bone marrow stromal cells were harvested according to
the protocol described by Peister [24], with some in
house modifications [25]. Media was changed for every
3rd day, subsequently after 1 to 2 weeks cells were disso-
ciated using Trypsin/EDTA for 4 min at 37°C and plated
according to the experimental setup.
Osteoblast differentiation
Osteogenic differentiation of BMSCs; cells were plated
at high densities; 20 × 103 cells/cm2 in 24 well plates for
staining and in 6 well plates for RNA harvesting contain-
ing complete expansion media (CEM): Iscove modified
Dulbecco medium (IMDM; GIBCO, Cat. No. 21980) con-
taining 12% FBS (FBS; GIBCO), 100 U/ml penicillin
(GIBCO), 100 μg/ml streptomycin (GIBCO) and 12 μM
L-glutamine (GIBCO, Cat. No. 25030) supplemented with
osteogenic cocktail; 10 nM dexamethasone (Sigma), 10
mM β – glycerol-phosphate (Sigma) & 50 μg/ml Vitamin C
(Sigma). Media was changed every 3rd day until day 10 and
then cells were stained for Alkaline phosphatase (ALP) and
harvested for RNA isolation.
Cytochemical staining
Alkaline phosphatase staining
Cells were fixed with acetone/citrate buffer pH 4.2
(11/2:1) for 5 min at room temperature and stained
with Naphtol-AS-TR-phosphate solution for 1 h at room
temperature. Naphtol-AS-TR-phosphate solution consists
of Naphtol-AS-TR-phosphate (Sigma) diluted 1:5 in H2O
and Fast Red TR (Sigma) diluted 1:1.2 in 0.1 M Tris
buffer (OUH pharmacy), pH 9.0, where both solutions
were mixed 1:1. Cells were counterstained with Mayers-
Hematoxylin for 5 min at room temperature.
Alizarin red staining for mineralized matrix
Cells were fixed with 70% ice-cold ethanol for 1 h at −20°C,
and stained with 40 mM alizarin red S (AR-S; Sigma), pH
4.2 for 10 min at room temperature.
Quantitative real time mouse osteogenesis RT2 profiler™
PCR array
Quantitative mRNA expression of 84 genes related to
osteogenic differentiation was performed using Mouse
osteogenesis RT2 profiler™ PCR array (Super array Bio-
science Corporation, Frederick, MD, USA) [26,27]. RNA
was isolated from WT and Terc-/- BMSCs (n = 3), at day
10 of osteoblast differentiation, using Trizol® and accord-
ing to the manufacture’s protocol. Concentration of RNA
was determined spectrophometrically by absorbance at
260 nm with GeneQuant pro (Biochrom Ltd.). First strand
complementary DNA was synthesized from 2 μg of total
RNA using a commercial revertAid H minus first strand
cDNA synthesis kit (Fermentas, Helsingborg, Sweden),
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biological replicates were pooled and PCR array analysis
was done according to manufacturer instructions with
RT2 Real Time™ SYBER GREEN PCR Master mix (Super
array Biosciences, Corporation). Quantitative Real Time
PCR array was performed in an iCycler IQ detection system
(Bio-Rad, Herlev, Denmark).
Results
Defective proliferation of Terc-/- BMSCs during in vitro
osteoblast differentiation
We have previously shown that Terc-/- BMSCs exhibit
stunted proliferation as evident by BrdU labelling during
normal culture [12], while proliferation was not assessed
during in vitro osteoblast differentiation. To examine the
proliferation rate during in vitro osteogenesis, we differ-
entiated WT and Terc-/- BMSCs into osteoblasts and
counted cells at different time points. Terc-/- BMSCs dem-
onstrated reduced proliferation rate compared to WTcon-
trols at day 3 and day 7 (Figure 1A). Moreover, population
doubling analysis during normal culture revealed that
Terc-/- BMSCs took more time to double with population
doubling level (PDL) of 2.44 initially to PDL of 0.214 after
40 days compared to WT BMSC’s PDL of 2.64, which
later dropped to PDL of 1.3 after 40 days (Figure 1B). Simi-
larly, population doubling time (PDT) of Terc-/- BMSCsFigure 1 Telomerase deficient BMSCs exhibited impaired in vitro oste
doubling time and level. A) Short term proliferation of Terc-/ and WT BMS
3 and 7. B) Long term proliferation of Terc-/- and WT BMSCs. Population do
1.89 days by WT BMSCs at early passage and later increased to 23 and 3.8
BMSCs - according to the protocol described in material and methods. Alkalin
day 10 of osteoblast differentiation. Data are represented of means ± SD of thwas 2.1 days, and later increased to 23 days at later pas-
sages, while PDT of WT BMSCs was around 1.89 days at
early passage and 3.8 days around day 40 (Figure 1B). Also
cumulative population doubling (CPD) stands at 8.62 for
Terc-/- BMSCs at day 40 compared to 15.4 for WT BMSCs
at day 40 (Figure 1B).
Telomerase deficiency causes atypical osteoblast
differentiation of BMSCs
We have previously shown that telomerase deficient
BMSCs and bones exhibit signs of defective osteogenesis
with more detailed data on long bones compared to
BMSCs [12]. Thus we aimed at delving into more de-
tailed study of telomerase deficient BMSCs. Next task
was to select a time point that could detect most of the
super array genes to conclude, connect and delineate
the functional dysregulation of genetic molecules during
osteoblast differentiation due to telomerase deficiency.
Thus we did a pilot experiment on WT BMSCs differen-
tiation into osteoblasts considering three different time
points (Additional file 1: Figure S1A); day 3, 7 and 10,
and selected day 10 to perform super array based on
observed data. We differentiated Terc-/- BMSCs into os-
teoblasts until day 10, where we analyzed ALP activity
by ALP staining and matrix mineralization by Alizarin
Red staining. Terc-/- BMSCs showed decreased in vitrooblast differentiation and proliferation with reduced population
Cs, equal number of cells were plated at day 0 and counted at day 1,
ubling time (PDT); Terc-/- BMSCs PDT of 2.1 days compared to PDT of
days, respectively. C) In vitro osteoblast differentiation of Terc-/- and WT
e phosphatase (ALP) (upper row) and Alizarin Red (lower row) staining at
ree independent experiments. *p≤ 0.05.
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day 10 (Figure 1C).
Osteogenic super array gene profiling displayed defective
osteoblast differentiation and function in Terc-/- BMSCs
To study further, the effects of telomerase deficiency
during in vitro osteoblast differentiation we performed
Mouse Osteogenesis RT2 Profiler™ PCR Array as de-
scribed in material and methods. Data analysis revealed
defective osteoblast differentiation with differential ex-
pression of several genes at various phases of osteoblast
differentiation. Briefly, major changes were observed in
genes controlling extracellular matrix production which
accounted for 40% of the genes, followed by cell growth
and differentiation (24%), bone mineralization (16%),
skeletal development (14%) and transcription factors and
regulators (6%) respectively (Figure 2A). Moreover, during
PCR super array several of the genes were not amplifiedFigure 2 Differential gene expression profiles of telomerase deficient
A) Pei chart showing differential gene expression profiles associated with e
of transcription factors and regulators in Terc-/- BMSCs up-regulated (red bars)
development genes, known to be involved in bone mineralization, cartilage con
(green bars) in Terc-/- BMSCs relative to WT controls. Genes that were not amplif
Osteogenic super array data are represented as fold change relative to WT cont
C = control, I = induced, scale bar 500 μm.or detectable and were marked as ‘n.d’ (not detectable) in
the figures (Figures 2, 3, 4 and 5). Moreover, results are ar-
ranged and described according to functional gene group-
ing specified by super array bioscience cooperation.
Transcription factors and regulators
Noteworthy genes that affected this category include,
runt related transcription factor 2 (Runx2, -3.7), smad
family member 3 (Smad3, -4.7), twist – basic helix loop
helix transcription factor (Twist, -8.3) and vitamin D re-
ceptor (Vdr, -13.9) (Figure 2B).
Skeletal development
Several genes were found to be differentially expressed -
known to be involved in bone mineralization, cartilage
condensation and ossification (Figure 2C-E). Notable
genes that were down-regulated in Terc-/- BMSCs include
fibroblast growth factor receptor 2 (Fgfr2, -2.4) importantBMSCs employing mouse osteogenesis RT2 profiler™ PCR array.
ach stage of osteogenesis. B) Differentiation gene expression profiles
and down-regulated (green bars) relative to WT controls. C-E) Skeletal
densation and ossification, up-regulated (red bars) and down-regulated
ied or not detectable in the PCR array were marked as ‘n.d’ (not detectable).
rols of three independent biological replicates pooled together. Panel (A)
Figure 3 Differential expression of genetic molecules involved in bone mineral metabolism and cell growth during differentiation in
Terc-/- BMSCs. A & B) Differential expression of genes involved in bone mineral metabolism affecting calcium ion binding and phosphate
transport in Terc-/- BMSCs compared to WT controls. C-D) Differential transcriptional profiles of Terc-/- BMSCs during in vitro osteoblast
differentiation. Several genes with known involvement in osteoblast cell cycle, proliferation and differentiation were up-regulated (red bars) and
down-regulated (green bars) in Terc-/- BMSCs compared to control. Genes that were not amplified or not detectable in the PCR array were marked
as ‘n.d’ (not detectable). Osteogenic super array data are represented as fold change relative to WT controls of three independent biological replicates
pooled together.
Figure 4 Effect of telomerase deficiency on extracellular matrix (ECM) protein molecules during in vitro osteoblast differentiation of
BMSCs. A) Differential expression of genes involved in cell differentiation into ostoeblasts. B-E) Differential gene expression profiles of molecules
involved in extracellular matrix production in Terc-/- BMSCs – notable genetic molecules were related with ECM collagens, basement membrane
constituents, ECM proteases, ECM protease inhibitors and other molecules associated with ECM. Genes that were not amplified or not detectable
in the PCR array were marked as ‘n.d’ (not detectable). Osteogenic super array data are represented as fold change relative to WT controls of three
independent biological replicates pooled together.
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Figure 5 Other extracellular matrix (ECM) protein molecules affected by telomerase deficiency and differentiation time point re-ascertainment
by real time PCR. A) Other ECM molecules affected by Telomerase deficiency. B) Re-ascertainment of in vitro differentiation time point by comparing
three time points Day 3, 7 and 10 employing both control and Terc-/- BMSCs. Genes that were not amplified or not detectable in the PCR array were
marked as ‘n.d’ (not detectable). Osteogenic super array data are represented as fold change relative to WT controls of three independent biological
replicates pooled together.
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(Col11a1, -14), collagen type 2 alpha 1 (Col2a1, -5.7),
dentine matrix protein (Dmp1, -2.5) and phosphate regu-
lating neutral endopeptidase on chromosome X (Phex,
-3.8) involved in cartilage condensation (Figure 2C-E).
Other noteworthy genes include runt related transcription
factor 2 (Runx2, -3.7), bone morphogenetic protein 2
(Bmp4, -1.5), bone morphogenetic protein 6 (Bmp6, -2.3),
transforming growth factor beta 1 (Tgfb1, -7.4) and vita-
min D receptor (Vdr. -13.9) (Additional file 1: Figure S1B).
Bone mineral metabolism
Similarly, expression level of several genes known to
be involved in calcium ion binding and phosphate
transport were reduced in Terc-/- BMSCs compared to
WT (Figure 3A & B). Most significantly affected (down-
regulated) genes in calcium ion binding category include
cartilage oligomatrix protein (Comp, -1.8), matrix metal-
lopeptidase 2 (Mmp2, -2.3), bone morphogenetic pro-
tein 1 (Bmp1, -4.7) and vitamin D receptor (Vdr, -13.9).
In phosphate transport category collagens were adversely
affected – notable down-regulated genes include colla-
gen type 1 alpha 1 (Col1a1, -40), collagen type 1 alpha 2(Col2a1, -22), collagen type 2 alpha 1 (Col2a1, -5.7) and bone
morphogenetic protein 5 (Bmp5, -3.9) (Figure 3A & B).
Cell growth and differentiation
Genes that were involved in cell cycle regulation and
were down-regulated in Terc-/- BMSCs include integrin
beta 1 (Itgb1, -2.4), transforming growth factor beta 1
(Tgfb1, -7.4) and platelet derived growth factor alpha
(Pdgfa, -1.7) (Figure 3C & D). Several growth factors and
receptors engaged in cell proliferation and differentiation
were also down-regulated in Terc-/- BMSCs, such as col-
ony stimulating factor 2 (Csf2, -2.5), colony stimulating
factor 3 (Csf3, -1.9), bone morphogenetic protein 4
(Bmp4, -1.5), bone morphogenetic protein 6 (Bmp6, -2.3),
insulin like-growth factor 1 (Igf1, -3.3), insulin like-growth
factor receptor 1 (Igfr1, -1.7), transforming growth factor
beta receptor 3 (Tgfbr3, -2.17) and growth differentiation
factor 10, (Gdf10, -5.4) (Figure 4A and Additional file 1:
Figure S1C). Similarly, genes important for cell diffe-
rentiation were also markedly reduced in Terc-/- BMSCs
compared to WT BMSCs, most conspicuous were bone
morphogenetic protein 4 (Bmp4, -1.5), bone morphogenetic
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(Igf1, -3.3), runt related transcription factor 2 (Runx2, -3.7)
and twist – basic helix loop helix transcription factor
(Twist, -8.4) (Figure 4A and Additional file 1: Figure S1C).
Extracellular matrix (ECM) protein
Among the ECM proteins, collagens were most signifi-
cantly affected in Terc-/- BMSCs compared to WT BMSCs
(Figures 4B-E & 5A). Most significant reduction was
observed in collagen type 11 alpha 1 (Col11a1, -14), colla-
gen type 1 alpha 1 (Col1a1, -40), collagen type 1 alpha 2
(Col1a2, -22) and collagen type 2 alpha 1 (Col2a1, -5.7).
Among ECM proteases, matrix metallopeptidase 10
(Mmp10, -23) was markedly reduced in Terc-/- BMSCs
(Figures 4B-E & 5A). Other most conspicuous molecules
crucial for ECM production include, biglycan (Bgn, -4.2),
alkaline phosphatase (Akp2, -3.6), cartilage oligomatrix
protein (Comp, -1.8), dentine matrix protein 1 (Dmp1,
-2.5), integrin alpha 2 (Itga2, -16.4), integrin alpha 2b
(Itga2b, -8.5), collagen type 12 alpha 1 (Col12a1, -4.3)
(Figures 4B-E & 5A).
Re-ascertainment of data analysis time point by real
time PCR
We already compared genes expression at three different
time points (day 3, 7 and 10) employing control samples,
where suitable expression level can be ascertained to
perform data analysis (Additional file 1: Figure S1A).
However, next obvious question was to re-confirm the
appropriateness of data analysis time point, using con-
trol and test samples, by comparing different time
points; day 3, day 7 and day 10. Therefore, we selected
two genes from each functional gene grouping category
of osteogenic super array for comparative gene expres-
sion analysis using Real time PCR. Real time PCR data
further suggest, that under available resources and time
point options, day 10 provide better reckoning of osteo-
blast specific expression of genes (Runx2, Msx1, Bmp2,
Dmp1, Igf1, Col1a1, Vdr, Gdf10 and Mmp8) pertinent
for investigating the role of telomerase deficiency during
in vitro osteoblast differentiation (Figure 5B).
Discussion
Telomerase deficiency has been shown to effect BMSCs
differentiation into osteoblast, adipocytes and chondro-
cytes [28]. We have previously shown that telomerase
deficiency causes reduced proliferation, enhanced senes-
cence and up-regulation of cell cycle inhibitors in tel-
omerase deficient BMSCs [12], while its over-expression
has been shown to enhance BMSCs proliferation and
osteogenic differentiation; both in vitro and in vivo, with
no signs of in vitro senescence [29]. In this study, we per-
formed more detailed expression profiling of dysregulated
genes affected during in vitro osteoblast differentiation inTerc-/- BMSCs. Data suggested that telomerase deficiency
caused more significant dysregulation in genes involved in
osteogenic commitment and extracellular matrix produc-
tion during the differentiation process.
Osteoblastogenesis is a multifaceted and intricate pro-
cess regulated by temporal and spatial expression of tran-
scription factors, cytokines, growth factors, hormones and
morphogens in a stage specific manner [30,31]. Subtle dif-
ferences in any of these factors can affect the coordinated
effort towards lineage commitment to lineage maturation.
Our data demonstrated that telomerase deficiency caused
differential gene expression profiles emanating from dysreg-
ulation of transcription regulation to extracellular matrix
production and bone mineralization during the course of
in vitro osteoblast differentiation. Reduction in Runx2,
Twist and Vdr in Terc-/- BMSCs, possibly suggest initial
inadequacy in osteogenic lineage commitment. Neverthe-
less, Msx1, another transcription regulator, was signifi-
cantly up-regulated in Terc-/- BMSCs with documented
role in cell proliferation and differentiation during embry-
onic development, affecting Runx2 expression in neural
crest cells and during osteoblast differentiation [32]. Thus,
up-regulation of Msx1 in Terc-/- BMSCs could suggest a
positive feedback signal to enhance Runx2 expression,
since Runx2 lies downstream of Msx1 [33]. Additionally,
down-regulation of Twist in Terc-/- BMSCs presumably
favour osteoblast specific genes expression because litera-
ture evidence suggests that down-regulation of Twist
genes (Twist1 and Twist2) is required to initiate osteoblast
specific gene expression [34]. These data suggest that
telomerase deficiency causes inadequate transcriptional
control over BMSCs lineage commitment towards osteo-
blast. However, insensitivity of mesenchymal progenitors
towards the differentiation signals could possibly come
from the senescent cells. It is plausible that senescent cells
secrete several inhibitory cytokines and mortifying en-
zymes affecting cell responses towards the inducing sig-
nals - ending up in the reduction of agile progenitor’s pool
that could respond to give a more affirmative response to-
wards the induction signals.
Furthermore, marked reduction in genes involved in
cellular growth, differentiation and skeletal develop-
ment such as, Pdgfa, Itgb1, Smad3, Dmp1, Phex, Fgfr2,
Col11a1 and Tgfb1, suggest that telomerase deficiency re-
sulted in defects from proliferative phase to mineralization
phase of osteogenesis. For example, Itgb1 has been shown
to promote and regulate cell spreading, proliferation and
cytoskeleton integrity to influence cell differentiation [35],
Dmp1 is vital for mineralization of bone and later func-
tioning of osteocytes crucial for proper bone re-modelling
process [36]. The reduced levels of Fgfr2 mRNA, upon de-
letion of Twist, have been associated with decreased
mRNA levels of Runx2, Bsp and Oc [37]. Col11a1 has
been shown to suppress terminal osteoblast differentiation
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Lef1 with Col11a1 promoter sans b-catenin [38]. Seem-
ingly, there exist numbers of genetic signals, in Terc-/-
BMSCs, opposing or affecting osteoblast differentiation
processes. While in parallel there were signals with in-
sisting support for osteoblast differentiation process as
evident from various gene expression profiles, such as
down-regulation of Col11a1, which suppresses terminal
osteoblast differentiation [38], down-regulation of Tgfb1,
known to muffle osteoblastic proteins, especially Runx2
via Smad3 [39] to further suppress Alp and Oc expression
[38,40] and up-regulation of Egf, Fgfr2 and Fgf1, known
pro-mitogenic signals [41-43], vital for osteoprogenitors
expansion to attain osteoblast maturation stage. Further-
more, these pro-osteoblastic efforts were reinforced by
up-regulation of other genes such as Bmpr1b, Col5a1
and Cdh11 known to support osteoblast differentiation
process at various phases and by distinct mechanisms
[44-46]. Besides, these data should be interpreted with
great care owing to cell culture heterogeneity and vari-
ation in telomere lengths that can result in muddled re-
sponses. Nevertheless, osteoblast suppressive responses
are dominant over signals favouring osteoblast differenti-
ation process. Moreover, it would be interesting to have
different cell culture options with differences in tel-
omerase inflection to better understand the dynamics
of telomerase enzyme and it’s physiologically relevant
enzymatic activity that could possibly favour optimal
osteoblast differentiation.
Furthermore, extracellular matrix is a central compo-
nent of cellular microenvironment that plays crucial role
in cell behaviour and function by regulating cell adhesion,
migration, apoptosis, proliferation and differentiation [47].
Strikingly, several collagens associated with ECM, such as
Col1a1, Col1a2, Col2a1 and Col11a1 were dysregulated in
our data. Among all the collagens present in the ECM,
Collagen type 1 (Col1a1) is a major protein present in the
ECM of the bone and plays an important role in bone
mineralization [48]. Similarly, Itga2 deficiency in mice, an-
other component of ECM - significantly reduced in Terc-/-
BMSCs, has been shown to reduce joint pathology, such
as reduction in pannus formation, joint inflammation and
cartilage erosion [49]. Our data and literature evidences
suggest that telomerase deficiency causes severe modifi-
cations in ECM related collagens and integrins that
could also synergise the unfavourable outcome regard-
ing BMSCs proliferation, survival and differentiation,
since ECM has much demanding role in osteoblast dif-
ferentiation rather than any other cell differentiation
process. Moreover, data also suggested the presence of
mixed signals, ECM protective and EMC un-protective.
For example, down-regulation of Serpinh1, an ECM
protease inhibitor involved in ECM degradation, impli-
cated in osteogenesis imperfecta and encodes collagenchaperone protein Hsp47 [50] and up-regulation of
Mmp8 - alleviating joint inflammation and bone erosion
[51] coupled with down-regulation of Mmp10 involved
in promoting cartilage degradation [52], respectively.
Conclusion
In conclusion, telomerase deficiency causes inadequate
in vitro differentiation of BMSCs into osteoblasts mani-
fested by dysregulation of genes involved in various
phases of osteoblast differentiation. It is plausible that
initial defect at transcriptional level ramify into regula-
tory changes in the expression of genes associated with
specific phases of the differentiation process. It is also
likely, that telomerase deficient cells undergoing senes-
cence are not actively participating in the differentiation
process, thus lacking optimal signal threshold levels suit-
able for osteoblast commitment and proliferation, thereby
affecting osteoprogenitors pool size. Data also suggest that
Terc-/- BMSCs seems quite perplexed in their response to-
wards differentiating signals because osteoblast suppres-
sive and osteoblast promoting signals were evident from
the super array PCR data or dual responses suggest a posi-
tive and negative feedback loop mechanisms to assimilate
a coordinated effort towards osteoblast differentiation.
However, it is possible that Terc-/- BMSCs in culture
exhibit differences in their telomere lengths, where cells
having critically short telomeres undergoing senescence
are associated with gene regulation oblivious of osteoblast
differentiation, while cells having optimal lengths are giv-
ing due responses towards the differentiation signals.
Other likely possibility is the conformational changes in
the chromatin owing to telomere shortening, thus regulat-
ing undesirable gene expression pattern altering normal
response of BMSCs towards osteogenic differentiation.
Therefore, regulating telomerase expression at optimal
physiological levels to attain uniform telomere lengths,
using molecular, chemical and pharmacological ways, and
to avoid senescence and malignant transformations could
further improve our understanding of the mechanisms as-
sociated with defective differentiation due to telomerase
deficiency and telomere length dynamics.Additional file
Additional file 1: Figure S1. Telomerase deficiency in BMSCs caused
defects in skeletal development genes and several growth factors and
receptor molecules involved in cellular growth and differentiation. A) Gene
expression profiles of WT BMSCs at three different time points during
in vitro Osteoblast differentiation. B) Genes affected by telomerase
deficiency in BMSCs during their in vitro osteogenesis involved in
skeletal development. C) Notable growth factors and receptor molecules
affected in Terc-/- BMSCs and having association with cellular growth and
differentiation process. Genes that were not am,plofied or not detectable in
the PCR array were marked as ‘n.d’ (not detectable). Osteogenic super array
data are represented as fold down-regulation relative to WT controls of
three independent biological replicates pooled together.
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